PMID- 26996750
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20210105
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
VI  - 25
IP  - 6
DP  - 2016 Jun
TI  - Does Prior Antiplatelet Treatment Increase the Risk of Hemorrhagic Transformation 
      and Unfavorable Outcome on Day 90 after Intravenous Thrombolysis in Acute 
      Ischemic Stroke Patients?
PG  - 1366-70
LID - S1052-3057(16)00065-3 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2016.01.038 [doi]
AB  - BACKGROUND: The effect of prior antiplatelet (AP) therapy on the risk of 
      hemorrhagic transformation (HT), and on functional outcomes of acute ischemic 
      stroke (AIS) after intravenous thrombolysis (IVT), is not known. We performed a 
      retrospective analysis to determine whether history of AP therapy is associated 
      with post-thrombolysis HT and poor prognosis in AIS patients. METHODS: Data 
      pertaining to 145 patients with AIS, who underwent IVT between October 2008 and 
      January 2015, were analyzed. The patients were divided into 2 groups based on 
      whether or not they had received prior AP therapy. Neurological outcomes at 
      24 hours and 3 months after IVT therapy were assessed. Intergroup difference in 
      cost of treatment was also evaluated. A multivariate logistic regression model 
      was used to identify independent predictors of post-thrombolysis HT. RESULTS: 
      Among 145 patients, 23 (15.8%) had received prior AP therapy. On multivariate 
      analyses, older age (odds ratio [OR]: 1.084; confidence interval [CI], 
      1.028-1.144) and prior AP therapy (OR: 3.318; CI, 1.172-9.398) were found to be 
      independent predictors of HT. CONCLUSION: In this study, prior AP therapy was 
      independently associated with post-thrombolysis HT in AIS.
CI  - Copyright (c) 2016 National Stroke Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Chen, Siyan
AU  - Chen S
AD  - Departmentof Neurology, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China. Electronic address: chensy0330@163.com.
FAU - Lu, Xia
AU  - Lu X
AD  - Department of Neurology, First People's Hospital of Jiaxing, Jianxing, China.
FAU - Zhang, Wanli
AU  - Zhang W
AD  - Departmentof Neurology, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Han, Zhao
AU  - Han Z
AD  - Department of Neurology, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Yang, Wen
AU  - Yang W
AD  - Department of Neurology, Jinhua Central Hospital, Jinhua, China.
FAU - Huang, Xuerong
AU  - Huang X
AD  - Departmentof Neurology, The Third Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Jin, Xiaoping
AU  - Jin X
AD  - Department of Neurology, Taizhou Hospital, Taizhou, China.
FAU - Wang, Zhimin
AU  - Wang Z
AD  - Department of Neurology, Taizhou Hospital, Taizhou, China.
FAU - Liang, Haiyan
AU  - Liang H
AD  - Department of Neurology, Municipal Hospital of Taizhou, Taizhou, China.
FAU - Qiu, Weiwen
AU  - Qiu W
AD  - Department of Neurology, Lishui Central Hospital, Lishui, China.
FAU - Cheng, Jianhua
AU  - Cheng J
AD  - Departmentof Neurology, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Shao, Bei
AU  - Shao B
AD  - Departmentof Neurology, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20160317
PL  - United States
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National 
      Stroke Association
JID - 9111633
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Brain Ischemia/diagnosis/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/*adverse effects
MH  - Humans
MH  - Infusions, Intravenous
MH  - Intracranial Hemorrhages/*chemically induced/diagnosis
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
MH  - Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke/diagnosis/*drug therapy
MH  - Thrombolytic Therapy/*adverse effects
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute ischemic stroke
OT  - hemorrhagic transformation
OT  - intravenous thrombolysis
OT  - prior antiplatelet therapy
EDAT- 2016/03/22 06:00
MHDA- 2017/04/12 06:00
CRDT- 2016/03/22 06:00
PHST- 2015/09/07 00:00 [received]
PHST- 2016/01/11 00:00 [revised]
PHST- 2016/01/24 00:00 [accepted]
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
AID - S1052-3057(16)00065-3 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2016.01.038 [doi]
PST - ppublish
SO  - J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1366-70. doi: 
      10.1016/j.jstrokecerebrovasdis.2016.01.038. Epub 2016 Mar 17.